Sygnature Discovery

MARCH 14, 2025

Collaboration with customers and Sygnatures computational chemists ensures quality hit identification using computational chemistry triage, counter screens, and orthogonal assays. Sygnature Discovery integrates cutting-edge automation to ensure efficiency and precision in our HTS processes.

Biochemical Assays 52

Biochemical Assays Fragment Screening Computational Chemistry Assay Development 52

DrugBank

JUNE 27, 2024

Opportunities in Drug Repurposing There is great potential for drug repurposing to unlock treatments for rare and neglected diseases, where traditional drug development is too costly. Network pharmacology, also known as systems medicine, integrates different drug discovery paradigms, offering a comprehensive view of drug actions.

Drugs 98

Drugs Pharma Companies Clinical Trials Computational Chemistry 98

DrugBank

OCTOBER 17, 2024

Computational chemistry and molecular modeling techniques can predict potential drug candidates' binding affinity and pharmacokinetic properties, enabling the selection of the most promising compounds for further development.

Drug Development 98

Drug Development Metabolic Stability Clinical Trials Drugs 98

Drug Target Review

NOVEMBER 1, 2023

The mission of the CCDD is to discover novel small-molecule therapeutics for the treatment of cancer and progress them to hypothesis testing phase 1 clinical trials. For example, in the screening stage of a project we are trying to find initial starting points for optimisation by our medicinal and computational chemistry colleagues.

Fragment Screening 96

Fragment Screening Biochemical Assays Small Molecule Biophysical Assays 96

The Pharma Data

NOVEMBER 15, 2020

R&D collaboration building on Lead Pharma’s expertise in the discovery, design and optimization of small molecule treatments. “Our ambition is to develop life-changing treatments for patients. Lead Pharma may receive payments of up to €260 million plus royalties on sales. About Lead Pharma.

Small Molecule 52

Small Molecule Licensing Licensing Disease 52

Molecular Design

SEPTEMBER 27, 2023

Drug discovery scientists, especially those with backgrounds in computational chemistry and cheminformatics, don’t always appreciate the importance of controlling exposure and the uncertainty in intracellular concentration always makes for a good stock question for speakers and panels of experts.

Computational Chemistry 90

Computational Chemistry Drugs Laboratories Production 90

Drug Target Review

MAY 31, 2024

One of the first programs I worked on in my career was drugging a novel, epigenetic target which had potential implications for the treatment of cancers. Could you share an example of a specific project or research that you have worked on and the impact it has had in your field?

Organic Chemistry 45

Organic Chemistry Computational Chemistry Small Molecule Disease 45